Technology area: Biotechnology & Pharmaceuticals
10 pending office actions • 8 art units • 10 examiners • 0 of 10 (0%) have an AI response strategy ready • 8 patents granted in the last 365 days
Regenxbio Inc. has 10 pending office actions in Biotechnology & Pharmaceuticals, making active docket coordination important. The matters are assigned to 10 distinct examiners across 8 distinct art units. This distribution indicates that the portfolio spans multiple examination groups rather than a single centralized review channel.
The examiner allocation is especially broad because each pending matter has a distinct examiner, while the art-unit distribution is narrower than the examiner distribution. That pattern can require separate communication and response strategies across technical units. It also limits the value of relying on one examiner-specific prosecution approach.
BOESEN, AGNIESZKA is the busiest examiner, with 1 pending matter. No examiner has a larger recorded share, so docket oversight should emphasize consistent claim strategy, disclosure support, and deadline control across the full set of applications.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (20%) |
| Double-patenting only | 1 (10%) |
| Double-patenting + other | 2 (20%) |
| Multi-statute (no §101) | 5 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BOESEN, AGNIESZKA | 1 | 68.6% | +21.8% |
| POPA, ILEANA | 1 | 21.7% | +15.7% |
| HUDSON, AMY ROSE | 1 | 74.8% | +11.7% |
| LY, KRISTINA ELISABETH | 1 | 37.5% | +100.0% |
| HUMPHRIES, NICHOLAS ADAM | 1 | 34.2% | +76.6% |
| BLUMEL, BENJAMIN P | 1 | 70.7% | +30.6% |
| SPENCER, ANDREA LYNNE MORRIS | 1 | 20.0% | +37.5% |
| PENNINGTON, KATIE LEIGH | 1 | 31.8% | +58.8% |
| TSAY, MARSHA M | 1 | 45.5% | +52.8% |
| YU, TIAN NMN | 1 | 55.6% | +19.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17285362 | METHOD FOR MEASURING THE INFECTIVITY OF REPLICATION DEFECTIVE VIRAL VECTORS AND VIRUSES | YU, TIAN NMN | 50d overdue |
| 18034042 | VECTORIZED TNF-ALPHA ANTAGONISTS FOR OCULAR INDICATIONS | HUMPHRIES, NICHOLAS ADAM | 33d |
| 18557155 | MICRODYSTROPHIN GENE THERAPY ADMINISTRATION FOR TREATMENT OF DYSTROPHINOPATHIES | POPA, ILEANA | — |
| 18030630 | FORMULATIONS FOR SUPRACHOROIDAL ADMINISTRATION SUCH AS HIGH VISCOSITY FORMULATIONS | SPENCER, ANDREA LYNNE MORRIS | — |
| 17638517 | TREATMENT OF DIABETIC RETINOPATHY WITH FULLY-HUMAN POST-TRANSLATIONALLY MODIFIED ANTI-VEGF FAB | PENNINGTON, KATIE LEIGH | — |
| 17600418 | RECOMBINANT ADENO-ASSOCIATED VIRUSES AND USES THEREOF | TSAY, MARSHA M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18257820 | METHOD OF PRODUCING A RECOMBINANT VIRUS PARTICLE | LY, KRISTINA ELISABETH | 60d overdue |
| 17285362 | METHOD FOR MEASURING THE INFECTIVITY OF REPLICATION DEFECTIVE VIRAL VECTORS AND VIRUSES | YU, TIAN NMN | 50d overdue |
| 18034042 | VECTORIZED TNF-ALPHA ANTAGONISTS FOR OCULAR INDICATIONS | HUMPHRIES, NICHOLAS ADAM | 33d |
| 18777913 | ANION EXCHANGE CHROMATOGRAPHY FOR RECOMBINANT AAV PRODUCTION | BOESEN, AGNIESZKA | — |
| 18557155 | MICRODYSTROPHIN GENE THERAPY ADMINISTRATION FOR TREATMENT OF DYSTROPHINOPATHIES | POPA, ILEANA | — |
| 18264364 | METHODS FOR PREVENTING CARDIAC OR SKELETAL DEFECTS IN DISEASES INCLUDING MUCOPOLYSACCHARIDOSES | HUDSON, AMY ROSE | — |
| 18030616 | FORMULATIONS FOR SUPRACHOROIDAL ADMINISTRATION SUCH AS GEL FORMULATIONS | BLUMEL, BENJAMIN P | — |
| 18030630 | FORMULATIONS FOR SUPRACHOROIDAL ADMINISTRATION SUCH AS HIGH VISCOSITY FORMULATIONS | SPENCER, ANDREA LYNNE MORRIS | — |
| Art Unit | Apps |
|---|---|
| 1671 | 2 |
| 1631 | 2 |
| 1672 | 1 |
| 1633 | 1 |
| 1636 | 1 |
| 1634 | 1 |
| 1656 | 1 |
| 1681 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18777913 | ANION EXCHANGE CHROMATOGRAPHY FOR RECOMBINANT AAV PRODUCTION | BOESEN, AGNIESZKA | 1672 | DP | Non-Final OA | — | Pending | Jul 19, 2024 |
| 18557155 | MICRODYSTROPHIN GENE THERAPY ADMINISTRATION FOR TREATMENT OF DYSTROPHINOPATHIES | POPA, ILEANA | 1633 | §103Other | Non-Final OA | — | Pending | Oct 25, 2023 |
| 18264364 | METHODS FOR PREVENTING CARDIAC OR SKELETAL DEFECTS IN DISEASES INCLUDING MUCOPOLYSACCHARIDOSES | HUDSON, AMY ROSE | 1636 | §102§103§112DP | Non-Final OA | — | Pending | Aug 04, 2023 |
| 18257820 | METHOD OF PRODUCING A RECOMBINANT VIRUS PARTICLE | LY, KRISTINA ELISABETH | 1671 | §103Other | Final Rejection | 60d overdue | Pending | Jun 15, 2023 |
| 18034042 | VECTORIZED TNF-ALPHA ANTAGONISTS FOR OCULAR INDICATIONS | HUMPHRIES, NICHOLAS ADAM | 1631 | §103§112 | Non-Final OA | 33d | Pending | Apr 26, 2023 |
| 18030616 | FORMULATIONS FOR SUPRACHOROIDAL ADMINISTRATION SUCH AS GEL FORMULATIONS | BLUMEL, BENJAMIN P | 1671 | §102§103§112DP | Non-Final OA | — | Pending | Apr 06, 2023 |
| 18030630 | FORMULATIONS FOR SUPRACHOROIDAL ADMINISTRATION SUCH AS HIGH VISCOSITY FORMULATIONS | SPENCER, ANDREA LYNNE MORRIS | 1631 | §103§112 | Non-Final OA | — | Pending | Apr 06, 2023 |
| 17638517 | TREATMENT OF DIABETIC RETINOPATHY WITH FULLY-HUMAN POST-TRANSLATIONALLY MODIFIED ANTI-VEGF FAB | PENNINGTON, KATIE LEIGH | 1634 | §102§103§112 | Non-Final OA | — | Pending | Feb 25, 2022 |
| 17600418 | RECOMBINANT ADENO-ASSOCIATED VIRUSES AND USES THEREOF | TSAY, MARSHA M | 1656 | §103§112 | Non-Final OA | — | Pending | Sep 30, 2021 |
| 17285362 | METHOD FOR MEASURING THE INFECTIVITY OF REPLICATION DEFECTIVE VIRAL VECTORS AND VIRUSES | YU, TIAN NMN | 1681 | §103§112 | Final Rejection | 50d overdue | Pending | Apr 14, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialRegenxbio Inc. has 10 pending office actions as of October 2026, spread across 8 art units and 10 examiners.
Agnieszka Boesen has the most, with 1 of Regenxbio Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
